The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients

Rijnstate Hospital10 enrolled

Overview

Study to assess the feasibility of an external ultrasound fixator (ProbeFix)

Rationale: Study to assess the feasibility of an external ultrasound fixator (ProbeFix) Objective: Cardiac output measurements using transthoracic ultrasound (TTE) with and without the use of the probeFixR will be evaluated in terms of accuracy. The TTE measurements will be combined with another form of cardiac output measurements (FlotracR) after a passive leg rasing (PLR) test. Study design prospective, feasibility study Study population: Adult Intensive Care patients ( \> 18 years) Intervention (if applicable): Consecutive adult patients on the ICU in which the FlotracR monitor is used will be evaluated after detection of hypovolemia. Main study parameters/endpoints: * Percentage of patients in which the ProbeFixR can be used * The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR Although no side effects are to be expected the investigators will monitor the patients after the ProbeFix is removed for any skin damage. The investigators will grade this damage into 3 categories: * No skin marks * Mild skin marks (no treatment necessary) * Severe skin marks (surgical or medical treatment necessary) * If the patients are awake the investigators will ask them whether they felt the ProbeFixR to be unpleasant on a scale of 0-10 (0 being: I did not feel anything and 10 being very unpleasant).

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Hypovolemia

Interventions

ProbefixDEVICE

A passive leg raising test will be done twice to assess the fluid response. Changes in cardiac output are measured using TTE with and without the use of the Probefix.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult Intensive Care patients ( \> 18 years), with hypovolemia detected with Flotrac (SVV \> 10%) Exclusion Criteria: * Pregnancy * Atrial fibrillation or other irregular heart rhythm * Pulmonary edema * PLR not possible (eg neurological disease, spinal trauma, restricted limb movement, deep venous thrombosis, or any other reason as indicated by the attending intensivist). * age \< 18 years

Locations (1)

Rijnstate Hospital

Arnhem, Netherlands

Outcomes

Primary Outcomes

The correlation between the measurements done by FlotracR and TTE with and TTE without ProbeFixR

A Bland and Altman plot will be constructed and the limits of agreement will be calculated.

Time frame: 8 weeks

Secondary Outcomes

Skin marks as possible side effect; scored as 'no skin marks', 'mild skin marks (no treatment necessary)' or 'severe skin marks (surgical or medical treatment necessary)'

Percentages will be reported.

Time frame: 8 weeks

Is the Probefix unpleasant on a scale of 0-10

The VAS scale will be reported as mean with standard deviation if normally distributed or as median and inter-quartile range if not normally distributed.

Time frame: 8 weeks

Patients in which the ProbeFixR can be used

Percentages will be reported.

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.